Build a new business line
Grow in tandem with the booming genomic testing market. With the accelerating development of novel therapeutic approaches, there will be great demand for technologies that enable genomic profiling. Especially in neurology, a field plagued by a dearth of effective, patient-friendly tests.
Pharma companies
Maximize clinical trial efficiency by performing more accurate cohort selection up-front.
De-risk your clinical trials by tracking early how trial participants' genomic profiles react to new therapeutics.
Diagnostics firms
Generate new revenue streams with a view to developing this RUO test into an IVD.
The precedent is set: Genomic tests are getting adopted and reimbursed by payors.
Laboratories
The FBB Test works on standard sequencers. Our products fit seamlessly into current lab workflows.
Optimize the utilization of your NGS sequencers. No new hardware required – standard NGS sequencers can handle our test.
Partner
Maximize clinical trial efficiency, capture new testing business
